Popkin, Roy J.
September 1961
Angiology;Sep1961, Vol. 12 Issue 9, p427
Academic Journal
1. The medical management of peripheral vascular diseases has kept up with the other fields of medicine and surgery. 2. Many new agents have been developed for specific therapy and many agents used for other diseases have been found to be beneficial in peripheral vascular disorders. These agents consist of intravascular fibrinolysins, sulfonyl-ureas with fibrinolytic activity, ‘desludging’ agents, vasodilators and cortisone compounds. 3. Graduated exercises have been found beneficial for several reasons. Exercise has been found to be of value not only for the mechanical effect of muscle contractions upon the blood vessels but (a) au increased fibrinolytic activity of the blood, (b) inhibition of sludging, (c) development of a collateral circulation and (d) reduction of atherosclerosis in cholesterol fed animals.


Related Articles

  • ATITUDINE TERAPEUTICÄ‚ ÃŽN ISCHEMIA CRITICÄ‚ A MEMBRELOR INFERIOARE. Brănişteanu, Roberta; Datcu, M. D.; Popa, R.; Aursulesei, Viviana // Jurnalul de Chirurgie;2011, Vol. 7 Issue 4, p615 

    Critical limb ischemia is the most severe manifestation of peripheral arterial disease. The gold of this study is to assess the prevalence of risk factor, associated comorbidities and therapeutic approach in a group of patients hospitalized in the Medical Clinic with critical limb ischemia....

  • Vasodilators: minoxidil and drugs used in peripheral vascular and cerebral disorders. Lowe, Gordon D.O. // British Medical Journal (Clinical Research Edition);4/16/1983, Vol. 286 Issue 6373, p1262 

    Examines the use of vasodilators for the treatment of peripheral vascular and cerebral disorders in Great Britain. Increase of peripheral venous pooling of blood; Accounts on the adverse effects of minoxidil; Mechanisms of hypertrichosis.

  • Peripheral vascular disease. Dillavou, Ellen; Kahn, Mark B. // Geriatrics;Feb2003, Vol. 58 Issue 2, p37 

    Indicates that peripheral vascular disease (PVD) occurs as a result of arterial narrowing or obstruction that restricts blood flow to distal tissues. Common sign of generalized atherosclerosis; Prevalence of PVD in various age groups; Need for aggressive medical management to prevent...

  • inositol nicotinate.  // Royal Society of Medicine: Medicines;2002, p304 

    The article presents information on inositol nicotinate, a vasodilator which can be used orally to help improve blood circulation to the hands and feet when this is impaired, for example, in peripheral vascular disease. Inositol nicotinate is administered orally.

  • Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ARIF, SALLY A.; D'SOUZA, JENNIFER; GIL, MONIKA; GIM, SUZANNA // American Journal of Health-System Pharmacy;10/1/2015, Vol. 72 Issue 19, p1615 

    Purpose. The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, dosage and administration, cost, and place in therapy of vorapaxar in the secondary prevention of atherosclerotic events are reviewed. Summary. Vorapaxar is a highly selective, reversible antagonist of...

  • naftidrofuryl oxalate.  // Royal Society of Medicine: Medicines;2002, p381 

    The article presents information on the vasodilator naftidrofuryl oxalate. The drug can be used to treat peripheral vascular disease and Raynaud's phenomenon. The drug is administered orally or by intravenous infusion. Its side-effects include nausea and pain in the abdomen, rash and has effects...

  • Peripheral Arterial Disease. Taylor, Michelle // Podiatry Review;Sep/Oct2013, Vol. 70 Issue 5, p4 

    The article provides information on peripheral arterial disease (PAD), which is known as poor circulation or hardening of the arteries and commonly occurs when the arteries supplying the lower limbs become obstructed. Atherosclerosis in the western world is a major cause of PAD. It mentions the...

  • Revised national guidelines for antithrombotic therapy. Linden, Belinda // British Journal of Cardiac Nursing;Jun2013, Vol. 8 Issue 6, p268 

    The article discusses the key features of the revised Scottish Intercollegiate Guidelines Network (SIGN) National Clinical Guideline 129, with regards to indications and management for antithrombotic therapy. Some of the SIGN recommendations pertaining to antiplatelet agents, parenteral...

  • Is cilostazol more effective than pentoxifylline in the treatment of symptoms of intermittent claudication? Weismantel, David // Journal of Family Practice;Feb2001, Vol. 50 Issue 2, p181 

    This article presents a study which examined the effectiveness of cilostazol over pentoxifylline in the treatment of symptoms of intermittent claudication. The study population is composed of patients with stable moderate to severe symptoms of intermittent claudication and confirmed peripheral...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics